Cerebonin 120 mg

/ Dr. Samuelov

Dementia syndrome: Adults from 18 years on take 1 film-coated tablet (corresponding to 120 mgGinkgo biloba dry extract EGb 761®) 2 times per day.
Vertigo, adjuvant tinnitus treatment: Adults from 18 years on take 1 film-coated tablet (corresponding to 120 mg Ginkgo biloba dry extract EGb 761®) 1 to 2 times per day.
Mode of application: When taken twice daily, one film-coated tablet should be taken in the morning and one in the evening. When taken once daily, the film-coated tablet should be taken in the morning. Do not take the film-coated tablets in a lying position. The film-coated tablets have to be taken unchewed with a sufficient quantity of liquid (preferably with a glass of water). The intake is independent of meals. There is no data concerning crushing or cutting the film-coated tablet.
Children and adolescents: The drug is not recommended for use in children and adolescents under the age of 18 years.
Duration of application
Dementia syndrome: Duration of the treatment should last for at least 8 weeks. If the disease symptoms do not show any improvement or even worsen after a therapeutic period of 3 months, it should be checked by the physician whether further treatment is justified.
Vertigo: Application over a longer period than 6 to 8 weeks bears no therapeutic advantage.
Tinnitus: The adjuvant treatment should be carried out for at least 12 weeks. If no therapeutic success is observed after 6 months, no further improvement is to be expected after a longer period of treatment.

For the symptomatic treatment of mental losses due to organic brain syndrome within the framework of a general therapeutic concept for dementia syndromes having as major symptoms: Deficient memory, disturbances of concentration, depressive mood, dizziness, tinnitus and headache.
The primary target group includes patients with demential syndrome in primary degenerative dementia, vascular dementia and mixed forms of both.
Individual response to the treatment cannot be predicted.
Note: Prior to starting treatment with Ginkgo extract, clarification should be obtained as to whether the pathological symptoms encountered are not based on an underlying disease requiring a specific treatment.
– Vertigo of vascular and involutional origin.
– Adjuvant treatment in case of tinnitus of vascular and involutional origin.

Hypersensitivity to Ginkgo biloba or to any of the excipients, pregnancy.

Not recommended for use in children and adolescents under the age of 18 years due to insufficient data on safety and efficacy. In case of increased tendency to bleeding (haemorrhagic diathesis) and in case of simultaneous treatment with coagulation-inhibiting drugs, this pharmaceutical preparation should only be used after having consulted with a physician. Single reports indicate the possibility that Ginkgo-containing preparations can increase bleeding tendency. This preparation should therefore be discontinued before surgical interventions. It cannot be excluded that the application of Ginkgo preparations promotes the occurrence of seizures in epileptic patients. This may be related to the content in 4’-O-methylpyridoxin. Patients with rare hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take this drug.
See prescribing information for full details.

There are no verified data on the frequency of the undesirable effects observed during treatment with Ginkgo biloba-containing preparations, since these undesirable effects have become known through single reports from patients, physicians or pharmacists.
According to these reports, the following undesirable effects may occur during treatment with this drug:
Bleeding from single organs may occur in particular in case of concomitant use of coagulation-inhibiting preparations such as phenprocoumon, acetyl salicylic acid or other non-steroidal antirheumatics. Allergic shock is possible in hypersensitive persons; furthermore, allergic skin reactions (reddening, swelling, itching) may occur.
Furthermore, mild gastrointestinal disturbances, headache, dizziness or enhancement of already existing dizziness can occur.
See prescribing information for full details.

In case of concomitant application of this drug with coagulation-inhibiting drugs (such as phenprocoumon, warfarin, clopidogrel, acetyl salicylic acid and other non-steroidal antirheumatics) it cannot be excluded that the effect of these preparations is enhanced. As for all medicinal preparations, it cannot be excluded that this drug acts on the metabolization of different other medicinal preparations via cytochrome P450-3A4,-1A2,-2C19 which may influence the potency and/or duration of the effect of the preparation concerned. There are not sufficient investigations available on these effects.
See prescribing information for full details.

Pregnancy: Contraindicated  during pregnancy.
Lactation: As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in breast milk.
See prescribing information for full details.

Symptoms from intoxication have not been reported up to now.
See prescribing information for full details.